Spin-offs

Ona Therapeutics was created in 2019 and is specialised in the discovery and development of therapeutic biologics targeting tumour metastatic-initiating cells and lipid metabolism. This therapeutic approach has the potential to prevent the formation of metastases and eliminate existing ones in multiple types of cancer.

<p>Logo Nostrum Biodiscovery</p>

Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and, specifically, in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of third-generation drugs based on peptidomimetics for human diseases. The company’s strategy is based on peptidomimetics, molecules able to modulate the activity of undruggable targets, such as Protein-Protein Interactions (PPIs).

Omnia Molecular was devoted to the design and development of anti-infectives targeted at difficult-to-treat infections. Lead compounds were synthesized and optimized using a proprietary technology platform and proved effective in several biological assays.
It has suspended its activities in 2016.